Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059290
Filing Date
2025-04-28
Accepted
2025-04-28 16:05:18
Documents
22
Period of Report
2025-06-18

Document Format Files

Seq Description Document Type Size
1 DEF 14A eypt-20250428.htm   iXBRL DEF 14A 1643325
2 GRAPHIC img260004928_0.jpg GRAPHIC 99780
3 GRAPHIC img260004928_1.jpg GRAPHIC 6484
4 GRAPHIC img260004928_2.jpg GRAPHIC 3687
5 GRAPHIC img260004928_3.jpg GRAPHIC 99780
6 GRAPHIC img260004928_4.jpg GRAPHIC 17608
7 GRAPHIC img260004928_5.jpg GRAPHIC 572626
8 GRAPHIC img260004928_6.jpg GRAPHIC 584411
9 GRAPHIC img260004928_7.jpg GRAPHIC 357408
10 GRAPHIC img260004928_8.jpg GRAPHIC 343638
  Complete submission text file 0000950170-25-059290.txt   7497098

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20250428.xsd EX-101.SCH 18362
24 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20250428_htm.xml XML 205207
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-51122 | Film No.: 25880245
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)